Immucor, Inc. (BLUD)

solid company. undervalued.

undervalued

Upthumb. Strong cash flow. 22% sales growth rate. 3.7 quick ratio. Zero debt. High gross margins.

solid financial status and strong market share

Following BullishBabo. Immucor's stock price was pummelled a few months ago due to news of an FDA review. The price still hasn't recovered. Potential catalysts for recovery will be: (1) good news from the FDA and (2) a general upsurge in medical stocks. Downside is limited by the company's reasonable valuation.

Debt free and highly profitable, right industry. Price change vs S&P puts this company into the "buy" category for me.

I use their products. Sometimes we'll get a shipment of Immucor product in on our shift, and, being very busy, forget to refrigerate it immediately. So we get written up and scolded by management. Their products are very expensive. Boy they must make a lot of money! : )

This stock is downgraded because of FDA review. The FDA is tough but they don't want to put a company, providing essential services out of business. Immucor is responding to FDA requirements and they are a strong company.

growing net cash, growing cash, growing profit, low debt, high ROI

Betting on good earnings to push this stock back into the 20's.

Low relative PE, good star ranking, PEG & 09 PE still below normal - bottom fishing 7/20 picks.

Good company all around and should do well regardless of economy, IMO.

Don't know a ton about BLUD, except that the financials are solid. Debt-free, good ROE and other margins. Profits and revenues were a solid growth story last few years, and have held steady during the recession. Likely market-beater from here for longer-term.

favs

2/33 in Health Care Supplies -(74.6 @ A/A+)

Siding with tenmiles and others on the positive financial aspects of this company. Also the recent sell off and 15% drop open up an even better buying window.

BLUD was hit hard by the DOJ investigation and then hit again in June by the FDA threatening to revoke their ability to sell their blood reagents. I think that the market over reacted to the FDA news on top already low prices. BLUD says they have been working to fix the quality issues related to the FDA for some time now.

Looks like it is being held down only by this pending lawsuit, everything else looks good. I'll take my chances.

tenmiles

Bought these bastardos at like 14. But I am poor, so I could'nt buy too much... I think I'm going to sell if it gets to $20.

Anyone see any reason why that's a bad idea? I suppose it could jump up if the anti-trust stuff proves baseless - but is it smart to wait? Is a bird in hand better than two in the bush?